Major M&A Deals Face Shareholder Scrutiny as Law Firm Probes Fair Valuation

Halper Sadeh LLC, a prominent investor rights law firm, has launched formal investigations into four significant corporate transactions, alleging potential breaches of fiduciary duty and violations of federal securities laws. The firm is examining whether shareholders in $SLNO (Soleno Therapeutics), Forian Inc., $MKC (McCormick & Company), and $CYCN (Cyclerion Therapeutics) received fair consideration and complete disclosure in their respective mergers and acquisitions. The investigations underscore growing investor concerns about transaction pricing and governance practices in an increasingly active M&A landscape.

The Four Transactions Under Investigation

The law firm's inquiries span several high-profile deals across different sectors, each raising distinct shareholder protection concerns:

Soleno Therapeutics' Sale to Neurocrine Biosciences

Soleno Therapeutics entered into an agreement to be acquired by Neurocrine Biosciences, a commercial-stage biopharmaceutical company. Halper Sadeh is investigating whether the transaction price adequately compensates Soleno shareholders for the company's assets and future prospects, and whether the board of directors fulfilled its fiduciary obligations in negotiating the deal terms.

Forian's Acquisition by CEO-Led Consortium

Forian's situation presents a classic conflict-of-interest scenario. The company agreed to be acquired by a consortium led by the company's own Chief Executive Officer. This self-dealing structure raises immediate red flags regarding board independence and whether management's personal financial interests superseded shareholder value maximization. Halper Sadeh is examining whether minority shareholders received fair treatment in this transaction.

McCormick & Company's Foods Business Merger

McCormick & Company ($MKC), the global spice and seasonings manufacturer, initiated a merger involving Unilever's Foods business. This complex transaction raises questions about valuation methodology, strategic rationale, and whether shareholders received adequate disclosure regarding the transaction's potential impact on company operations and shareholder returns.

Cyclerion Therapeutics' Merger with Korsana Biosciences

Cyclerion Therapeutics ($CYCN) agreed to merge with Korsana Biosciences. The investigation focuses on whether the transaction terms fairly value Cyclerion's operations and pipeline, particularly given the biotech sector's inherent valuation challenges.

Market Context: Rising M&A Scrutiny and Governance Concerns

Halper Sadeh's investigation reflects a broader trend of heightened shareholder activism and legal scrutiny surrounding corporate transactions. The investigation highlights several critical issues within the contemporary M&A landscape:

Governance and Fiduciary Duty Standards

In recent years, courts and regulatory bodies have increasingly focused on whether boards of directors conduct adequate processes before approving major transactions. Key concerns include:

• Whether independent directors actively negotiated deal terms
• Whether multiple bidders competed for the target company
• Whether financial advisors provided thorough valuations and fairness opinions
• Whether shareholders received complete and accurate disclosures

Disclosure Deficiencies

Merger proxies—documents sent to shareholders outlining transaction details and soliciting votes—frequently face criticism for inadequate disclosure. Investors and courts expect comprehensive information regarding:

• Financial projections and valuation methodologies
• Conflicts of interest among management and board members
• Alternative transaction structures that were considered
• Material risks associated with the proposed merger

Halper Sadeh specifically mentioned seeking additional disclosures from the four companies, suggesting their proxy statements or public filings may lack sufficient detail for shareholders to make fully informed voting decisions.

Self-Dealing Transactions

The Forian acquisition represents a particularly egregious conflict of interest, with the CEO leading the acquiring consortium. Such transactions demand the highest level of scrutiny, including fairness opinions, independent committee oversight, and disclosure of all material terms involving the interested party.

Investor Implications: Risk Factors and Shareholder Remedies

These investigations carry significant implications for shareholders and broader market dynamics:

Potential Financial Remedies

If Halper Sadeh's investigations substantiate their allegations, potential remedies for shareholders could include:

• Increased transaction consideration if current deal prices are deemed inadequate
• Damages awards compensating shareholders for losses resulting from fiduciary breaches
• Transaction rescission in extreme cases, though courts rarely order this remedy
• Corrective disclosures requiring companies to provide additional information before shareholder votes

Precedent and Settlement Patterns

Investor rights firms have achieved notable successes in similar investigations. Settlements often result in modest increases to deal consideration—typically ranging from 5-15% of transaction value—combined with enhanced disclosure and governance improvements. These outcomes suggest shareholders in the four companies under investigation may have legitimate grounds for claiming inadequate valuations.

Market Signaling Effects

The investigation sends a message to corporate boards and acquiring companies that aggressive deal pricing and inadequate disclosure processes invite legal challenges. Companies considering major transactions now face heightened incentives to:

• Conduct thorough, well-documented board processes
• Engage genuinely independent financial advisors
• Solicit multiple bids when feasible
• Provide comprehensive proxy disclosures

Failure to implement these best practices increases litigation risk and potential remediation costs.

Impact on Deal Completion

While investigations rarely block completed transactions, they can delay closings and create uncertainty during pending deals. For shareholders voting on the four transactions, Halper Sadeh's inquiries provide leverage to demand improved terms or additional disclosures before voting deadlines.

Looking Forward: Implications for Corporate M&A Activity

As institutional investors increasingly demand governance accountability, shareholder litigation surrounding M&A transactions will likely intensify. The investigations into Soleno, Forian, McCormick, and Cyclerion exemplify this trend, raising the stakes for boards overseeing major corporate transactions.

Corporations and their legal advisors should expect that significant transactions will face investor scrutiny and potential legal challenges. The cost of cutting corners on disclosure, process, and valuation rigor increasingly outweighs any short-term savings. Companies prioritizing robust governance, transparent processes, and comprehensive shareholder communication will minimize litigation risk and enhance deal execution confidence.

For investors in these four companies, Halper Sadeh's investigations provide a critical mechanism for challenging potentially inadequate transaction terms. Shareholders should carefully review proxy materials, consider the firm's findings, and cast informed votes on merger proposals. The coming weeks and months will reveal whether these investigations yield meaningful improvements to deal terms and shareholder protections—outcomes that extend well beyond these four companies into the broader corporate governance landscape.